Close Menu

helicase-dependent amplification

Great Basin this week announced the opening of a new manufacturing facility for its recently launched molecular diagnostics system and first test.

BioHelix is developing a low-cost, handheld, real-time fluorescence detection system capable of running assays based on the company's isothermal helicase-dependent amplification technology, the company disclosed this week.

Scientists from Great Basin Scientific and three university medical schools and hospitals have published research demonstrating that Great Basin's molecular diagnostic test for Clostridium difficile is as sensitive and specific as a competing molecular test based on real

This article has been corrected from a previous version that stated that Axxin disclosed in January that it is developing the NAT analyzer and iNAT platforms. In fact, Alere disclosed that it is developing these platforms.

Quidel said this week that it has received the CE mark for its AmpliVue C. difficile assay, making it the first commercially available test using Quidel's non-instrumented format.

The company has developed a cartridge-based, multiplex, sample-to-answer molecular testing platform in the same vein as Cepheid, and hopes to begin clinical trials for its first two tests for detecting Staphylococcus aureus in blood culture and Clostridium difficile in stool by early summer.

Pages

Three US lawmakers call on the Trump Administration to end its program to collect DNA from detained migrants, the Hill reports.

Soccer players who head the ball a lot and who have a certain APOE allele may be more likely to have memory problems, according to HealthDay.

Researchers in the US have developed a promising candidate vaccine against African swine fever, according to Bloomberg News.

In Cell this week: a quantitative proteomic atlas based on the Cancer Cell Line Encyclopedia, gene regulation and differentiation in Toxoplasma gondii, and more.